Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
55.82B
Market cap55.82B
Price-Earnings ratio
1.69K
Price-Earnings ratio1.69K
Dividend yield
Dividend yield
Average volume
800.45K
Average volume800.45K
High today
$427.05
High today$427.05
Low today
$405.51
Low today$405.51
Open price
$405.51
Open price$405.51
Volume
1.43M
Volume1.43M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 55.82B, Alnylam Pharmaceuticals(ALNY) trades at $422.50. The stock has a price-to-earnings ratio of 1690.52.

As of 2026-01-07, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $405.51 and $427.05. The current price stands at $422.50, placing the stock +4.2% above today's low and -1.1% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1.43M, compared to an average daily volume of 800.45K.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

ALNY News

TipRanks 8h
Alnylam assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Alnylam (ALNY) with an Outperform rating and $500 price target The firm says Amvuttra’s uptake in ATTR-CM has been impressive, d...

TipRanks 1d
Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns

Analyst William Pickering from Bernstein maintained a Buy rating on Alnylam Pharma and decreased the price target to $491.00 from $525.00. Claim 70% Off TipRank...

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.